More Articles


The changing nature of pharma sales: A conversation on many levels

Ulrich Neumann, (Feb 20, 2020)

The new approach to sales marries state of the art analytics with a classical approach to engagement

Medical: Pharma’s New North Star

Tom Disley, (Feb 20, 2020)

Already growing in importance, Medical Affairs will become a key differentiator for pharma campanies prepared to adapt and invest in the function

Time to embrace social media

Katie Osborne, (Feb 4, 2020)

Patients are turning to social media as never before and pharma needs to catch up

RWE: A new hope for rare disease

Lucy Fulford, (Jan 30, 2020)

RWE shows great promise in helping accelerate treatments for rare disease
Access and Evidence

Can we afford to pay for future cures?

Ulrich Neumann, (Jan 24, 2020)

Medical innovation is racing ahead of healthcare’s ability to innovate on payments, but new ideas are emerging
Access and Evidence

Into pharma's roaring twenties

Paul Simms, (Jan 14, 2020)

A new decade is here. And despite the incredible science, pharma is ill-equipped.
Patients and Medical

Scaling patient engagement for deeper insights and better outcomes

Lucy Fulford, (Jan 13, 2020)

Scaling patient engagement offers a cascade of benefits if only pharma can gather the right insights
Patients and Medical

Pharma’s new ally: The caregiver

Andrew Stone, (Jan 12, 2020)

Pharma has only just started thinking about how engaging with caregivers could unlock a range of valuable insights
Access and Evidence

Advancing RWE together with academia

Katie Osborne, (Jan 2, 2020)

Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust

Invest in MSLs to reap bigger gains

Andrew Stone, (Dec 31, 2019)

To get the most from MSLs pharma needs to invest, measure and empower